Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors

  title={Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors},
  author={Alexander K. Tsai and Eduardo Davila},
ABSTRACT Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to produce and deliver anticancer therapeutics that enhance cytotoxic T cell function and simultaneously inhibit immunosuppressive processes. Here, we review the potential of… 
CAR T‐cell therapy of solid tumors
The current state of CAR T‐cell therapy in solid cancers, the variety of concepts being investigated to overcome barriers as well as approaches aimed at increasing the specificity and safety of adoptive cell transfer are discussed.
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors
This study demonstrates self-tumor tropism of engineered cancer cells and their therapeutic potential when engineered with receptor self-targeted molecules, and it establishes a roadmap toward a safe clinical translation for different cancer types in primary, recurrent, and metastatic settings.
Enhancing tumor T cell infiltration to enable cancer immunotherapy.
This review summarizes mechanisms of how tumor tissue shapes immune suppressive microenvironment to prevent T cell access to the tumor site and focuses on current strategies to improve cancer immunotherapies through enhancing T cell infiltration.
Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality
The authors improve CAR T cell antitumor responses by simultaneously targeting a CAR to TCR locus and IL-12 to PD1 locus, placing the transgenes under a naturally regulated transcriptional network while disrupting unwanted signals.
T-Lymphocyte Homing: An Underappreciated yet Critical Hurdle for Successful Cancer Immunotherapy
How cancers thwart homing to escape immune-mediated destruction and raise awareness of the potential impact of immune checkpoint blockers on Teff cell homing are summarized.
Engineering Circulating Tumor Cells as Novel Cancer Theranostics
By incorporating a prodrug gene therapy system into self-homing CTCs, this study demonstrates the noteworthy ability of experimental C TCs to home to disseminated breast cancer lesions and shows exciting progress towards effective and targeted delivery of gene-based therapeutics to treat both primary and metastatic lesions.
Engineering “self-homing” circulating tumour cells as novel cancer theranostics
Using dual-luciferase BLI, this study demonstrates the noteworthy ability of experimental CTCs to home to disseminated breast cancer lesions and shows exciting progress towards effective and targeted delivery of gene-based therapeutics to treat both primary and metastatic lesions.
Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity
It is demonstrated that for gene-based bispecific antibody strategies, two-chain diabodies have a better safety profile than single-chain tandem scFvs (single-chain variable fragments), because their reduced tendency to form aggregates reduces the risk of inducing antigen-independent T-cell activation.


Clinical application of genetically modified T cells in cancer therapy
An introduction to the field of genetic engineering of T cells followed by details of their use against cancer in the clinic are provided.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.
EphA2-ENG T cells were activated and recognized tumor cells in an antigen-dependent manner, redirected bystander T cells to tumor cells, and had potent antitumor activity in glioma and lung cancer severe combined immunodeficiency xenograft models associated with a significant survival benefit.
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
In SCID-Beige mice with human ovarian cancer xenografts, IL-12 secreting CAR T cells exhibit enhanced antitumor efficacy as determined by increased survival, prolonged persistence of T cells, and higher systemic IFNγ.
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
It is reported that CAR T cells that target CD19 and contain a costimulatory domain from CD137 and the T cell receptor ζ chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL).
NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma, according to the expected mechanism of action of the transferred T cells.
Mesenchymal stem cells engineered for cancer therapy.
  • K. Shah
  • Biology
    Advanced drug delivery reviews
  • 2012
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
Results suggest that using the NFAT.hIL12.PA2 vector might be a promising approach to enhance adoptive cancer immunotherapy.
Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
This review focuses on recent clinical trials and analyzes the factors that determine clinical responses, including the composition of the CAR, the preparation of CAR-modified T cells, the clinical treatment schedule and the patient characteristics.